Other autoimmune diseases such as RA or T1DM are also possible future therapeutic targets for Kv1.3 inhibitors, based on the knowledge of the pathogenesis of these diseases and the results of in vivo studies in animal models already mentioned. The gene discussed is KCNA3; the disease is type 1 diabetes mellitus.